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Precision medicineCommunity-acquired pneumonia (CAP) is a common cause of pediatric hospital admission. Empiric antibiotic
therapy for hospitalized children with serious CAP now targets the most likely pathogen(s), including those
that may demonstrate significant antibiotic resistance. Cell-free plasma next-generation sequencing (CFPNGS)
was first made available for Pediatric Infectious Diseases physicians in June 1, 2017, to supplement standard-
of-care diagnostic techniques. A retrospective chart reviewwas performed for children hospitalizedwith CAP be-
tween June 1, 2017, and January 22, 2018, to evaluate the impact of CFPNGS. We identified 15 hospitalized chil-
dren with CAP without other underlying medical conditions for whom CFPNGS was performed. CFPNGS
identified a pathogen in 13 of 15 (86%) children compared with 47% for those using standard culture and PCR-
based methods alone. Changes in antibiotic management were made in 7 of 15 (47%) of children as a result of
CFPNGS.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pediatric community-acquired pneumonia (CAP) is a leading cause
of hospital admissions(Li and Tancredi, 2010; Grijalva et al., 2010,
2011)with a potentiallywide range of bacterial, viral, fungal, andmyco-
bacterial etiologies (Erlichman et al., 2017). In a large multisite study of
2638 children hospitalized with CAP, 89% had radiographic evidence of
pneumonia. Standard-of-care testing identified a viral infection in 66%
of patients, a bacterial infection in 8% of patients, and both a viral and
bacterial infection in 7% of patients (Jain et al., 2015). The current Pedi-
atric CAP Guidelines by the Infectious Diseases Society of America
(IDSA)/Pediatric Infectious Diseases Society (PIDS) recommend bloodCFPNGS, cell-free plasma next-
ciety of America; NGS, next-
lococcus aureus; HUS, hemolytic
erapy.
y.
c. The other authors have no fi-
The other authors have no con-
8-966-8092.
. This is an open access article underculture and viral testing for hospitalized patients with moderate to se-
vere community-acquired or complicated pneumonia in order to iden-
tify a pathogen(s). Recommended empiric treatment include a third-
generation cephalosporin for any patient with evidence of empyema,
with the addition of vancomycin or clindamycin if there are clinical, lab-
oratory, or imaging characteristics consistent with methicillin-resistant
Staphylococcus aureus (Bradley et al., 2011) (MRSA) infection.
In cases where cultures (e.g., blood, respiratory, pleural fluid) are
negative, physicians rely on epidemiology and clinical features to pre-
dict the most likely infectious organism(s) and guide empiric antibiotic
selection. This can be challenging as causal organisms have overlapping
clinical, radiographic, and laboratory features and/or atypical presenta-
tions. Additionally, the clinical course of complicated pneumonias is
often lengthy despite the presence of appropriate antimicrobial cover-
age (Breuer et al., 2018). In the absence of an identified pathogen, chil-
dren with serious infections may be treated with broad-spectrum
antibiotics for prolonged courses, due to concern for MRSA.
DNA sequencing of cell-free plasma(De Vlaminck et al., 2015; Long
et al., 2016; Hong et al., 2018) allows for detection of pathogen DNA de-
rived fromboth bloodstream infections and deeper body sites, including
cases where there has been antibiotic pretreatment prior to cultures
and in those with fastidious, difficult-to-culture organisms (Abril et al.,
2016). This case series reflects an institutional experience applyingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographics (n = 15).
Average age at admission (range) 4.16 years (0.7–10.7)
Male (% male) 8 (53%)
Length of hospital stay (range) 14.1 days (3–29.6)
Preceding viral illness 11 (73%)
Preceding antibiotic 8 (53%)
Consolidation on CXR 12 (80%)
Pleural effusion on CXR 10 (75%)
ICU admission 9 (60%)
Intubated 4 (27%)
Chest tube placed 9 (60%)
Surgical intervention 6 (40%)
Hemolytic uremic syndrome requiring CRRT 2 (13%)
CRRT = continuous renal replacement therapy.
Fig. 1. Culture results from the 15 patients for blood, respiratory, and pleural fluid/abscess
cultures.
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whose application has not been extensively studied. The current retro-
spective series in childrenwith CAPwas performed to assess the clinical
impact of this test compared with more traditional microbiologic
methods.
2. Patients and methods
A retrospective chart review was approved by the Human Re-
search Protections Program at the University of California San
Diego (HRP#180245) to evaluate the use of a cell-free plasma next-
generation sequencing (CFPNGS) plasma test in the management of
children with infections between June 1, 2017, and January 22,
2018. Inclusion criteria included previously healthy children with
CAP or complicated CAP as defined by the IDSA/PIDS guidelines, for
whom CFPNGS was ordered and who were discharged prior to Feb-
ruary 28, 2018. CFPNGS was a restricted test, ordered by pediatric
infectious diseases faculty through the electronic medical record.
No prospective, standardized criteria delineated when to obtain
CFPNGS; rather, it was at the discretion of the pediatric infectious
disease faculty. Children with chronic or complex underlying medi-
cal disease were excluded (i.e., underlying oncologic, genetic, or
chronic illnesses and/or use of immunomodulatory medications).
Chart review was performed using the electronic medical record
and incorporated into a REDCap database (Harris et al., 2009).
2.1. Sample processing
Peripheral blood samples were collected in a BD Vacutainer Plasma
Preparation Tube (PPT tube, Becton, Dickson and Company, Franklin
Lakes, NJ), centrifuged, and sent to the Karius laboratory (Redwood
City, CA) for CFPNGS (De Vlaminck et al., 2015). Cell-free DNA was ex-
tracted from plasma with a magnetic bead-based method (Omega
Biotek, Norcross, GA). DNA libraries were constructed using a modified
Ovation System V2 library kit (NuGEN, San Carlos, CA). Negative buffer-
only controls and positive controls consisting of healthy patient plasma
with addition of knownmixture ofmicrobial DNA fragmentswere proc-
essed in parallel, and all samples were sequenced on the Illumina
NextSeq 500.
2.2. Standard of care
Blood, urine, respiratory and pleural bacterial, fungal, and mycobac-
terial cultures, as well as multiplex PCR (EPlex Respiratory Pathogen
Panel) for detection of viral pathogens, were obtained at the discretion
of treating physicians. Samples for culture and CFPNGSwere not tempo-
rally matched at acquisition. Available standard care testing data were
includedwhen obtained within 72 h of the CFPNGS. Treating physicians
determined antimicrobial therapy. The pediatric infectious disease fac-
ulty assessed the effects of the CFPNGS test on the selection of antibiotic
therapy, subsequent procedures, and length of stay.
2.3. Analysis pipeline
Primary sequencing output files were processed using bcl2fastq
(v2.17.1.14) to generate demultiplexed sequencing reads files. Reads
were filtered based on sequencing quality and trimmed based on partial
or full adapter sequences. Sequence alignment of remaining reads was
performed against Karius' human and synthetic-molecules references
using Bowtie2 (Langmead and Salzberg, 2012). Sequencing reads that
exhibited alignment against the human or synthetic molecule references
were collected and filtered out from further analysis. The remaining reads
were aligned against Karius' proprietary microorganism reference data-
base using NCBI-blast (version 2.2.30). To determine whether the levels
observed in the samples exceeded those expected to originate from the
environment alone, a Poisson model parameterized by the estimatedbackground abundanceswas applied. Only taxa that rejected this null hy-
pothesis at high significance levels were reported and included in down-
streamanalyses. The entire process fromDNAextraction through analysis
was typically completed within 28 h.
3. Results
During the 8-month review period, a total of 125 children were ad-
mitted to the hospital with CAP, 31 of whom had CFPNGS testing ob-
tained at the discretion of the pediatric infectious disease attending
physician. Of these 31 children, 2 were excluded due to a diagnosed un-
derlying genetic disorder and 14 due to chronic comorbid conditions.
Patient demographics for the remaining cohort demonstrated an aver-
age age of 4.16 years and 53%male gender (Table 1). The average length
of hospital staywas 14 days, reflecting the fact that CFPNGS tended to be
requested only in cases of complicated pneumonia. In total, 10 of the 15
children were diagnosed with complicated CAP (pneumonia with pleu-
ral effusion or empyema), and 9 required admission to the pediatric in-
tensive care unit (PICU). Nine children were treated with thoracoscopy
for parapneumonic effusion or empyema, and 6 children required surgi-
cal intervention with video-assisted thoracoscopic surgery.
As indicated in Table 2, only 1 of 15 (6.7%) patients had a positive
blood culture at the time of admission. This culture yielded Streptococ-
cus pneumoniae, and CFPNGSwas also positive in this case. Pneumococci
were identified in 8 additional cases only by CFPNGS (Fig. 1, Table 2).
Respiratory cultures were obtained only in intubated children as endo-
tracheal aspirates and yielded putative causal organisms in 33% of the
study population (7 positive cultures from 5 patients). Of the respira-
tory samples, only 1 of the 3 patient cultures was concordant with the
CFPNGS diagnostic test (patient 1 identified S. pneumoniae from the
ETT and blood cultures as well as by CFPNGS). The 2 other patients
withpositive respiratory cultureswere patient 10 (identified Pseudomo-
nas aeruginosa from sputum and had negative CFPNGS) and patient 3
Table 2
Culture results.a
Patient Age
(y)
Diagnosis Culture results Time to
culture
result (h)
Organisms detected by CFPNGS Time to
CFPNGS
result (h)
Change in antibiotic
management due to
CFPNGS result
11 0.9 Empyema
Blood culture = Streptococcus pneumoniae; ETT
culture = Streptococcus pneumoniae, Moraxella catarrhalis;
Respiratory Viral Panel = Human metapneumovirus
20; 42.8;
3.5
Streptococcus pneumoniae 90 none
10 1.5 Abscess Respiratory Viral Panel = Coronavirus 5.5 Streptococcus pneumoniae 48.6
Clindamycin
discontinued for
ceftriaxone
monotherapy
13 2.4 Empyema ETT culture = MSSA 26.7 Streptococcus pneumoniae 245.3
Clindamycin
discontinued for
cefazolin
monotherapy
2 1 Empyema Negative NA Streptococcus pneumoniae 48
Clindamycin
discontinued for
ceftriaxone
monotherapy
5 4.5 Empyema Negative NA Streptococcus pneumoniae 103.8
Ceftaroline narrowed
to ceftriaxone
8 3.6 Empyema Negative NA Streptococcus pneumoniae 113.7
Ceftaroline narrowed
to ceftriaxone
7 2 Empyema Negative NA Streptococcus pneumoniae 102.7 none
15 2.7 Pneumonia Negative NA Streptococcus pneumoniae 60.1
Cefepime and
clindamycin
narrowed to
ampicillin
14 5.1 Pneumonia Cultures not obtained NA Streptococcus pneumoniae 69.8 none
1 10.7 Pneumonia Sputum culture = Pseudomonas aeruginosa 24.1 No organisms detected 100.3 none
6 6.4 Abscess Pulmonary abscess culture = Streptococcus intermedius 43.4
Streptococcus intermedius,
Aggregatibacter segnis, Epstein–Barr
virus
115.5 none
12 9.1 Abscess Respiratory viral panel = Coronavirus 2 No organisms detected 159.7 none
3 10.7 Pneumonia Negative NA
Fusobacterium nucleatum,
Epstein–Barr virus, Parvimonas
micra
54.7
Ceftriaxone
discontinued for
clindamycin
monotherapy
4 0.7 Pneumonia Negative NA
Pseudomonas aeruginosa, Burkholderia
multivorans, Human adenovirus C
104.9 none
9 1.1 Empyema Negative
Streptococcus pyogenes, Actinomyces
graevenitzii, Veillonella dispar,
Actinomyces odontolyticus
54 none
bacterial dx = 4/15; Viral dx = 3/15
Avg
Cx = 31.4 bacterial dx = 13/15 Avg = 98.1
47% change in
antibiotic
management
Avg
RVP = 3.6 viral dx = 3/15
D = diagnostic yield of testing obtained within 72 h of when the CFPNGS was obtained, which identified bacterial infections in 4 of 15 patients and viral infections in 3 of 15 patients as
compared to CFPNGS testing which yielded bacterial etiology in 13 of 15 patients and viral infections in 3 of 15 patients. The CFPGNS diagnosis positive patients led to a change of man-
agement in 7 of 15 patients (47%).
a Time for CFPNGSwas fromwhen bloodwas drawnuntil faxed result was scanned into electronicmedical record including laboratory processing, shipping, time at Karius Inc., and time
to get result into EMR after result faxed in.
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ETT culture and S. pneumoniae detected by CFPNGS). Three patients
had negative respiratory cultures despite a positive CFPNGS test: pa-
tient 13 identified Fusobacterium nucleatum, Epstein–Barr virus, and
Parviomonas micra detected on CFPNGS; patient 5 had S. pneumoniae
detected; and patient 15 had Streptococcus pyogenes, Actinomyces
graevenitzii, Veillonella dispar, and Actinomyces odontolyticus detected
on CFPNGS. Seven patients did not have respiratory cultures obtained.
Abscess fluid cultures obtained during placement of chest tube
thoracostomies were positive in only 1 of 9 children: Patient 11 isolated
Streptococcus intermedius from culture which was also detected by
CFPNGS, CFPNGS also detected Aggregatibacter segnis and Epstein–Barr
virus (Supplementary Table 1). A combination of conventional culture
methods yielded a bacterial diagnosis in only 27% of children; with in-
clusion of PCR testing for viral etiologies, only 40% of children had an or-
ganism identified. Of note, the viral etiologies detected on a respiratory
viral screen were not detected by CFPNGS due to the fact that RNA vi-
ruses are not detected this CFPNGS test. Patient 2 had coronavirus de-
tected from a nasopharyngeal swab and S. pneumoniae by CFPNGS,and patient 1 had human metapneumovirus detected from a nasopha-
ryngeal swab and S. pneumoniae from CFPNGS. Traditional testing
yielded a result on average 31.4 h (range 2–42.8 h) after the sample
was obtained, whereas CFPNGS yielded a result on average 98.1 h
(range 48–245.3 h) after the sample was obtained. The use of CFPNGS
independently identified a plausible bacterial pathogen in 86% of chil-
dren (13 of 15), with 60% (9 of 16) being positive for S. pneumoniae
(Table 1). The results of CFPNGS led to a change in antibiotic manage-
ment in 7 of 15 children (47%).
4. Discussion
In this retrospective study, CFPNGS identified 13 of 15 children to
have bacterial infectious etiologies that could potentially explain acute
pneumonia, as opposed to only 4 of 15 by traditional culture methods.
Since the introduction of the 7-valent Pneumococcal Conjugate Vaccine
(PCV7), followed by PCV13, there has been a decrease in pediatric hos-
pital admissions for pneumococcal pneumonia by 26–61%, but an in-
crease in staphylococcal pneumonia and unspecified empyema by
191L. Farnaes et al. / Diagnostic Microbiology and Infectious Disease 94 (2019) 188–1911.89- to 4.08-fold (Grijalva et al., 2010). Although there is an increase in
staphylococcal pneumonia, there may be a decrease in MRSA (Hultén
et al., 2018). Prior to the introduction of the pneumococcal conjugate
vaccine and the emergence of community-acquiredMRSA,many physi-
cians felt confident in the management of CAP based on a presumed di-
agnosis of pneumococcal or streptococcal pneumonia in children
admitted with CAP. However, given the changing epidemiological land-
scape of pediatric CAP,many physicians are now less confident in the di-
agnosis of fully susceptible S. pneumoniae in the absence of a positive
culture. Therefore, empiric antibiotic coverage has broadened to include
both S. aureus and multidrug-resistant pneumococcus. A consensus
guideline provided recommendations for the treatment of children
with severe CAP (or complicated CAP), but a paucity of strong prospec-
tive data did not support a high level of evidence to tailor treatment for
hospitalized children with culture-negative CAP (Fontela et al., 2017).
Lastly, the high prevalence in CAP patients who had antibiotic exposure
(53% in our cohort) prior to relevant culture samples, including blood
cultures, further reduces the sensitivity of cultures for pathogen detec-
tion using conventionalmethods. The use of CFPNGS has helped address
this issue by identifying the infectious etiology in children, even when
standard microbiologic cultures are negative. However, the lack of
rigorous data regarding sensitivity and specificity of CFPNGS has left
clinicians with minimal information in determining who would benefit
from CFPNGS.
Similar to previous studies (Lin et al., 2013; Krenke et al., 2016), we
found the yield of blood cultures and pleural effusion cultures to be low,
possibly secondary to antibiotic pretreatment. It is interesting to note
that there was not complete concordance between CFPNGS and tradi-
tional culture/viral PCR (see Table 2). This is an important challenge
for the application of a novel technology. Since this CFPNGS test does
not detect RNAviruses, therewas not concordancewith CFPNGS and re-
spiratory PCR testing. Also, local sampling in traditional ETT cultures
could explain why only 1 of 3 respiratory cultures were in agreement
with the CFPNGS since the respiratory sample was collected from the
upper airway and may not represent infection in the lung. Based upon
the detection of an organism (often Streptococcus pneumoniae) consis-
tent with the clinical presentation and with the site of infection in an
area of high blood flow (the lung) leading to increased shedding of
pathogen DNA into the blood, it seems reasonable to suggest that
CFPNGS may better reflect the nature of a pulmonary infection than a
sample obtained from the upper airway. Further rigorous studies are re-
quired to delineate the accuracy of CFPNGS versus traditional cultures.
CFPNGS may also present a challenge for infectious disease specialists
as organisms that are not common pathogens, such as Parvimonas
micra and Veillonella dispar, are identified in critically ill patients in com-
bination with other potentially pathogenic bacteria or in isolation. Does
this CFPNGS signal suggest co-infection, bacterial presence in another
part of the body (e.g., oral flora from a patient with gingivitis), or path-
ogenicity that is perhaps more common than we had previously
thought? As this technology becomes more broadly accepted, many of
these questions will have to be carefully examined.
As a direct result of CFPNGS, antibiotic selection was narrowed in 7
children (47% of the studied population) to beta-lactams rather than
continuing lincosamides or glycopeptides. Treating infectious diseases
clinicians believed that, with identification of a plausible organism,
broad coverage was no longer needed. Importantly, none of the children
treated with narrowed antimicrobial therapy based on CFPNGS results
were readmitted for late complications of CAP that could be attributed to
inappropriate antibiotic therapy. It should also be noted, however, that
the negative predictive value of this test has not been fully characterized.
This review addresses proof of concept of the clinical application of
CFPNGS in CAP in children. It does not compare CFPNGS to otherestablished diagnostic tests such as pathogen-specific bacterial real-
time PCR; however, such prospective, comparative studies would be
helpful to further differentiate the role of CFPNGS in the context of
other available tests in clinical practice.
This retrospective study has numerous limitations to the broad ap-
plicability of these findings. First, the study is limited in scope given
the small patient numbers and the uncontrolled nature of the decision
to consult the infectious diseases service and to have the consultant
order the CFPNGS test, although these data reflect a real-world experi-
ence. Children with CAP selected for CFPNGS evaluation represented a
more severely ill patient population, as demonstrated by a high rate of
PICU admission, prolonged hospitalization, and the predominance of
complicated CAP with empyema and/or parapneumonic effusion. The
average time to CFPNGS result was 4 days, although it is possible that
this timemay decrease as efficiencies in transport, processing, and anal-
ysis improve. Overall, these data suggest that CFPNGS in conjunction
with standard culture techniques may significantly increase diagnostic
yield and facilitate antibiotic selection in severe CAP.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.diagmicrobio.2018.12.016.References
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